TUESDAY, Could 11, 2021 (HealthDay Information) – Opioid-dependent individuals receiving subcutaneous depot buprenorphine have improved remedy satisfaction in comparison with these receiving sublingual buprenorphine, in response to a examine revealed on-line on October 10. Could in Open JAMA community.
Nicholas Lintzeris, MBBS, Ph.D., of the South Japanese Sydney Native Well being District, and colleagues carried out an open-label randomized trial in grownup opioid-dependent sufferers at six outpatient facilities from October 2018 to September 2019. A complete of 119 individuals have been enrolled and randomized to obtain weekly or month-to-month depot buprenorphine or day by day sublingual buprenorphine for 24 weeks (60 and 59 sufferers, respectively).
The investigators discovered that at week 24, the imply general satisfaction rating from the Remedy Remedy Satisfaction Questionnaire was considerably greater for the depot group in comparison with the sublingual group (imply, 82.5 vs. 74, three). After depot buprenorphine remedy, higher outcomes have been noticed for a number of secondary finish factors. A complete of 117 antagonistic drug reactions have been skilled by 39 individuals (65.zero %) within the depot buprenorphine group, whereas 12 individuals (20.three %) within the sublingual group skilled 21 antagonistic drug reactions.
“The outcomes of this examine constantly demonstrated the prevalence of injectable extended-release buprenorphine over the day by day oral formulation in lots of outcomes,” write the authors of an accompanying editorial. “Notably, the examine additionally discovered no difficulties in transitioning sufferers who have been receiving oral buprenorphine to the extended-release formulation, a discovering that has not beforehand been emphasised within the literature.”
A number of authors disclosed monetary ties to pharmaceutical corporations, together with Camurus AB.
Summary / Full textual content